Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Caribou Biosciences (CRBU) Income from Continuing Operations (2020 - 2025)

Caribou Biosciences has reported Income from Continuing Operations over the past 6 years, most recently at 28453000.0 for Q4 2025.

  • Quarterly Income from Continuing Operations rose 26.81% to 28453000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 148344000.0 through Dec 2025, up 10.97% year-over-year, with the annual reading at 148125000.0 for FY2025, 0.66% up from the prior year.
  • Income from Continuing Operations was 28453000.0 for Q4 2025 at Caribou Biosciences, up from 29400000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 13159000.0 in Q1 2021 and troughed at 47578000.0 in Q2 2025.
  • The 5-year median for Income from Continuing Operations is 29989000.0 (2022), against an average of 30217050.0.
  • Year-over-year, Income from Continuing Operations plummeted 664.48% in 2021 and then surged 44.86% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 18479000.0 in 2021, then tumbled by 65.47% to 30578000.0 in 2022, then fell by 22.45% to 37442000.0 in 2023, then dropped by 3.83% to 38875000.0 in 2024, then increased by 26.81% to 28453000.0 in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Income from Continuing Operations are 28453000.0 (Q4 2025), 29400000.0 (Q3 2025), and 47578000.0 (Q2 2025).